ALPHAEON expands partnership with TEOXANE Laboratories

Under terms of the agreement, TEOXANE will become the exclusive licensor and distributor of ALPHAEON’s advanced neuromodulator, EVOSYAL, across the EU, Central Europe, Russia and South Africa. The expanded partnership also provides TEOXANE with a right of first refusal to distribute all other ALPHAEON products and services that are brought to the European market.

ALPHAEON and TEOXANE began their partnership in August 2013, when ALPHAEON acquired an exclusive US license to market the full line of TEOXANE’s high-quality, market-leading products that include cosmeceuticals and hyaluronic acid-based wrinkle-fillers currently available in 90 markets outside of the US.

Two months later, ALPHAEON further strengthened its portfolio by gaining exclusive rights to market EVOSYAL, an advanced neuromodulator, in the US and several international markets.

ALPHAEON CEO Robert E Grant noted that the company is delighted to have expanded its partnership with TEOXANE.

"TEOXANE’s established direct and indirect sales channel will create market access for EVOSYAL across Europe," Grant added.

EVOSYAL is an advanced Botulinum toxin Type A neuromodulator developed by Daewoong Pharmaceutical. ALPHAEON acquired US and certain international rights in October of 2013.

EVOSYAL is both consistent in manufacturability and potency as a 900 kDa neuromodulator with high purity, which ALPHAEON believes will aid in achieving precise, predictable and long-lasting patient outcomes.

TEOXANE products contain 100% non-animal origin, resorbable hyaluronic acid. Hyaluronic acid dermal fillers are the most widely used aesthetic fillers worldwide. The company also has an extensive line of creams and other cosmeceuticals.